Top Markets
#1 Black Phoenix Black Phoenix +735.96%
#2 Beam Beam +32.49%
#3 SAFEcoin SAFEcoin +20.16%
#4 TENDIES TENDIES +18.60%
#5 Bless Bless +17.18%
#6 Biconomy Biconomy +16.86%
#7 EfficientFrontier EfficientFrontier +15.58%
#8 THORChain THORChain +14.80%
#9 pipedog pipedog +14.54%
#10 Tutorial Tutorial +12.76%
Coin of the day
Black Phoenix Black Phoenix
설정
언어
한국어
통화
USD
테마
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
주식 순위 #5575
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
주가
$36.98
마지막 동기화: 2026-08-26
시가총액
$2.58B
변동 (1일)
-0.67%
변동 (1년)
55.51%
국가
NL
거래 Pharvaris N.V. (PHVS)

카테고리

Healthcare
Pharvaris N.V. (PHVS)의 주가 이력
최고 종가: $35.74 (2026-08-01 기준)

최저 종가: $31.41 (2021-02-01 기준)
Pharvaris N.V.의 주가 이력 (2021 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) 9.05%
2025 33.94%
2024 -24.64%
2023 230.41%
2022 -49.99%
2021 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.38 41.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 47.75%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $148.35 491.02%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.63 -12.65%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $764.21 7.05%
CH